Author’s response: Critical need for robust surveillance in response to DENV-2 and SARS-CoV-2 cross-reactivity

References

1. Kow CS, Ramachandram DS, Hasan SS, Thiruchelvam K. Letter to the editor: Critical need for robust surveillance in response to DENV-2 and SARS-CoV-2 cross-reactivity. Euro Surveill. 2024;29(19):2400236.  https://doi.org/10.2807/1560-7917.ES.2024.29.19.2400236 
2. Klitting R, Piorkowski G, Rousset D, Cabié A, Frumence E, Lagrave A, et al. Molecular epidemiology identifies the expansion of the DENV2 epidemic lineage from the French Caribbean Islands to French Guiana and mainland France, 2023 to 2024. Euro Surveill. 2024;29(13):2400123.  https://doi.org/10.2807/1560-7917.ES.2024.29.13.2400123  PMID: 38551097 
3. Jakhar K, Sonar S, Singh G, Sarkar T, Tiwari M, Kaur J, et al. SARS-CoV-2 antibodies cross-react and enhance dengue infection. bioRxiv. 2023. doi: https://doi.org/10.1101/2023.10.09.557914 
4. Burton DR. Antiviral neutralizing antibodies: from in vitro to in vivo activity. Nat Rev Immunol. 2023;23(11):720-34.  https://doi.org/10.1038/s41577-023-00858-w  PMID: 37069260 
5. Bournazos S, Gupta A, Ravetch JV. The role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020;20(10):633-43.  https://doi.org/10.1038/s41577-020-00410-0  PMID: 32782358 
6. Li D, Edwards RJ, Manne K, Martinez DR, Schäfer A, Alam SM, et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021;184(16):4203-4219.e32.  https://doi.org/10.1016/j.cell.2021.06.021  PMID: 34242577 
7. Coutant F, Touret F, Pin JJ, Alonzo M, Baronti C, Munier S, et al. Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients: lessons from early variant infection and impact on shaping emerging variants. Emerg Microbes Infect. 2024;13(1):2307510.  https://doi.org/10.1080/22221751.2024.2307510  PMID: 38240255